Fyn depletion ameliorates tau\textsuperscript{P301L}-induced neuropathology

Guanghao Liu\textsuperscript{1}, Kimberly L. Fiock\textsuperscript{2}, Yona Levites\textsuperscript{3}, Todd E. Golde\textsuperscript{3}, Marco M. Hefti\textsuperscript{2} and Gloria Lee\textsuperscript{1,4*}

Abstract

The Src family non-receptor tyrosine kinase Fyn has been implicated in neurodegeneration of Alzheimer’s disease through interaction with amyloid β (Aβ). However, the role of Fyn in the pathogenesis of primary tauopathies such as FTDP-17, where Aβ plaques are absent, is poorly understood. In the current study, we used AAV2/8 vectors to deliver tau\textsuperscript{P301L} to the brains of WT and Fyn KO mice, generating somatic transgenic tauopathy models with the presence or absence of Fyn. Although both genotypes developed tau pathology, Fyn KO developed fewer neurofibrillary tangles on Bielschowsky and Thioflavin S stained sections and showed lower levels of phosphorylated tau. In addition, tau\textsuperscript{P301L}-induced behavior abnormalities and depletion of synaptic proteins were not observed in the Fyn KO model. Our work provides evidence for Fyn being a critical protein in the disease pathogenesis of FTDP-17.

Keywords: Fyn, Tau, Neurofibrillary tangles

Background

Alzheimer’s disease (AD), along with a subset of disorders such as frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17), corticobasal degeneration (CBD), progressive supranuclear palsy (PSP), and Pick’s disease, exhibit neurofibrillary tangles (NFTs) made up of aggregated hyperphosphorylated tau and are collectively known as tauopathies (reviewed by [78]). During the disease process, tau becomes abnormally hyperphosphorylated, detaches from microtubules, undergoes conformational changes, and ultimately aggregates to form NFTs (reviewed by [1, 21, 50, 52, 73]). AD also contains an additional neuropathological hallmark, amyloid β (Aβ) plaques. Although no mutations in the tau gene have been identified to cause AD, several mutations in tau, such as P301L, have been found to cause FTDP-17, where tau hyperphosphorylation, neurofibrillary tangle formation, and neurodegeneration occur in the absence of Aβ plaques [12, 29, 60, 79].

In neurons, tau is enriched in axons to regulate microtubule assembly (reviewed by [17, 36, 81]). We have previously reported that tau can also associate with the cytoplasmic face of the plasma membrane [7] and interacts with the SH3 domain of Src family non-receptor tyrosine kinases (SFK) such as Fyn and Src [41]. We found that Fyn phosphorylates tau at tyr18 [42] and that the tau-Fyn interaction increased the auto-phosphorylation of Fyn as well as the enzymatic activity of Fyn [71]. In addition, we reported that tau\textsuperscript{P301L} and other FTDP-17 tau mutants had a higher binding affinity to the Fyn SH3 domain, when compared to WT tau [4]. Subsequently, it was discovered that tau is also involved in targeting Fyn to the postsynaptic space in dendrites; Fyn then affects synaptic plasticity by phosphorylating the N-methyl-d-aspartate receptor (NMDAR) which facilitates the interaction between NMDAR and postsynaptic density 95 protein (PSD-95) [32, 56, 63]. It has also been reported that tau\textsuperscript{P301L} is selectively enriched in dendritic spines whereas WT tau is not [27, 82].
Initially, Fyn was linked to AD when it was discovered that neuritic plaques and dystrophic neurites in AD brain contained phospho-tyrosine and that Fyn was up-regulated in a subset of neurons and co-localized with NFTs in AD brain [26, 72, 90]. Subsequent studies using cell culture showed that Aβ treatment increased both Fyn activation and the level of tyrosine phosphorylated Aβ [48, 89]. In addition, genetic ablation of Fyn was protective against oligomeric Aβ-mediated neurotoxicity [39] while overexpressing Fyn in human amyloid precursor protein transgenic mice increased synaptic and cognitive impairments [10, 11]. Furthermore, inhibiting Fyn activity through a small molecule inhibitor in the triple transgenic AD mouse model also significantly rescued memory and cognitive impairments [33]. The mechanism by which Aβ activates Fyn involves the binding of soluble Aβ oligomers to cellular prion protein (PrPC) [85, 86]. The Aβ-PrPC complex then interacts with the metabotropic glutamate receptor (mGluR5) to activate intracellular Fyn kinase [84]. The effect of Aβ on Fyn activation has been linked to synaptic abnormality and behavioral deficits in APP mouse models (reviewed by [5, 6, 75]). Fyn has also been directly and indirectly implicated in the hyperphosphorylation of tau at disease-related sites. Firstly, Fyn has been reported to activate Cdk5 [67] and GSK-3 [43], two kinases that hyperphosphorylate tau on serine and threonine residues [24, 25, 47, 49, 58]. Secondly, we have found that phospho-tyr18-tau is present in neurofibrillary tangles in brains from AD patients [42] as well as brains from an FTDP-17 mouse model that expresses the tauP301L mutation [2, 4]. In addition, pY18-tau also co-localizes with activated Src family tyrosine kinases (SKF) in NFTs of FTDP-17 mouse brains [2]. In Aβ-mediated neurodegeneration, the importance of the tau-Fyn interaction has been supported by the finding that inhibition of the interaction ameliorated the toxic effects of Aβ oligomers [65].

In FTDP-17 mouse models, several changes induced by tauP301L have been reported, such as behavioral deficits, tau hyperphosphorylation, electrophysiological changes, and structural atrophy of dendritic spines with reduction of surface NMDA and AMPA receptors [16, 27, 28, 37, 59, 62, 64, 66]. However, the role played by Fyn in the disease pathogenesis of FTDP-17, where Aβ is absent, is unknown. In this study, we have used a viral gene transduction method to facilitate somatic brain transgenesis and to create an FTDP-17 tauopathy model. Our results establish Fyn as a critical protein involved in the pathogenesis of FTDP-17.

Methods

Mice
Fyn KO (C57BL/6;S129) mice were obtained from Jackson Laboratories (strain 002385). WT mice were generated by crossing the Fyn KO and Tau KO (C57BL/6, strain 007251) mice, as described [46]. In this way, the strain of the WT would be closer to that of the Fyn KO, minimizing strain related differences. Litter mate controls were not used. All procedures and animal care were approved by the University of Iowa Institutional Animal Care and Use Committee and in compliance with the NIH Guide for the Care and Use of Laboratory Mice.

AAV-tauP301L injection at postnatal day 0 (p0)
AAV2/8-tauP301L, produced by the University of Iowa Viral Vector Core, was injected intracerebroventricularly (ICV) into WT and Fyn KO mouse pups on postnatal day 0 (4.2e12 viral particles/μl; 2 μl/ventricle). ICV injections were performed as described [9], where newborn mice were anesthetized by placing on a cold pack and a 32-gauge needle was used to pierce the skull 2/5 way between eyes and bregma and inserted at 0.5 cm depth. Both right and left lateral ventricles were each injected with 2 μl of AAV. At 6 months of age, behavioral testing was performed. Subsequently, mice were deeply anesthetized with isoflurane then perfused with phosphate-buffered saline. The brain was removed and bisected along the midline. Half was drop-fixed in 4% paraformaldehyde overnight at 4 °C for histology, whereas the other half was frozen in liquid N2 after discarding the olfactory bulb, cerebellum, and midbrain. WT mice and Fyn KO mice injected with AAV-tauP301L were designated WT-AAV and Fyn KO-AAV, respectively. In AAV2/8, the expression of tauP301L was regulated by a cytomegalovirus enhancer/chicken beta actin (CBA) promoter, a woodchuck hepatitis virus post-transcriptional-regulatory element (WPRE) and the bovine growth hormone polyA [9].

Magnetic resonance imaging
Mice were imaged at 8 weeks of age. Varian Unity/Inova 4.7 T small-bore MRI system (Varian, Inc., Palo Alto, CA; Small Animal Imaging Facility, University of Iowa) with an in-plane resolution of 0.13 x 0.25 mm² and 0.6 mm slice thickness was used. Coronal images were collected and lateral ventricle volume sizes were analyzed with Imagej [8]. Quantification was carried out as previously described [46]. Fyn KO mice were divided by degree of hydrocephalus, with lateral ventricle volume of ≤ 0.2 units considered normal, 0.2 < x ≤ 2 units as
represented as

"normalized to those from WT with the WT values represented to tau5 and protein level values from Fyn KO-AAV were normalized to GAPDH levels; AT8 and pY18 signals were normalized from crude lysates, measured by tau5, were normalized to GAPDH levels; AT8 and pY18 signals were normalized to tau5 and protein level values from Fyn KO-AAV were normalized to those from WT-AAV. 19 WT-AAV and 7 Fyn KO-AAV mice were used for AT8 and tau5; 12 WT-AAV and 7 Fyn KO-AAV mice were used for anti-pY18-tau. For quantitating NeuN and PSD95 (Fig. 6), levels were first normalized to GAPDH and then normalized to WT-uninjected mice. At least 7 WT, 9 WT-AAV, 9 Fyn KO, and 9 Fyn KO-AAV mice were used.

Crude synaptosome preparations were prepared from the crude brain lysate as previously described [32]. Primary antibodies used to probe the crude synaptosome preparations were: Fyn3, tau5-HRP, and tau13 (as above); β-actin (JLA20 1:10,000 mouse monoclonal, Iowa DSHB); PSD-95 (EP2652Y, 1:1000 rabbit monoclonal, ThermoFisher); anti-pY18-tau (1:1000 rabbit polyclonal [42]); PSD95 (1:1000 rabbit polyclonal, Millipore Sigma); and NeuN (1:5000 mouse monoclonal, Millipore Sigma). Quantification of lightly exposed blots was done by densitometry using ImageJ. For Fig. 3, total tau levels from crude lysates, measured by tau5, were normalized to GAPDH levels; AT8 and pY18 signals were normalized to tau5 and protein level values from Fyn KO-AAV were normalized to those from WT-AAV. 19 WT-AAV and 7 Fyn KO-AAV mice were used for AT8 and tau5; 12 WT-AAV and 7 Fyn KO-AAV mice were used for anti-pY18-tau. For quantitating NeuN and PSD95 (Fig. 6), levels were first normalized to GAPDH and then normalized to WT-uninjected mice. At least 7 WT, 9 WT-AAV, 9 Fyn KO, and 9 Fyn KO-AAV mice were used.

Preparation of brain homogenates, crude synaptosomes, and western blot analysis

Mouse hemi-brains were homogenized in sucrose buffer (0.32 M sucrose, 1 mM NaHCO₃, 1 mM MgCl₂, 0.5 mM CaCl₂, 10 mM NaF, 1 mM NaVO₄, 1 mM AEBSF, 10 μg/ml pepstatin, 10 μg/ml leupeptin, 10 μg/ml aprotenin) and samples were centrifuged (1000 g, 10 min, 4 °C). The pellet, containing nucleus and cell debris, was discarded and the supernatant, containing cytosolic proteins, was retained as the crude brain lysate. An equal amount of 2X Laemmli sample buffer was added and heat-denatured for 5 min at 95 °C.

Western blotting of crude brain lysates has been previously described [41]. Primary antibodies used were: GAPDH (1:20,000 mouse monoclonal, Chemicon); Fyn3 (1:1000 rabbit polyclonal, Santa Cruz); tau5-HRP (1:10,000 mouse monoclonal, gift from late Dr. Lester Binder); AT8 (1:1000 mouse monoclonal, ThermoFisher); anti-pY18-tau (1:1000 rabbit polyclonal [42]); PSD95 (1:1000 rabbit polyclonal, Millipore Sigma); and NeuN (1:5000 mouse monoclonal, Millipore Sigma). Quantification of lightly exposed blots was done by densitometry using ImageJ. For Fig. 3, total tau levels from crude lysates, measured by tau5, were normalized to GAPDH levels; AT8 and pY18 signals were normalized to tau5 and protein level values from Fyn KO-AAV were normalized to those from WT-AAV. 19 WT-AAV and 7 Fyn KO-AAV mice were used for AT8 and tau5; 12 WT-AAV and 7 Fyn KO-AAV mice were used for anti-pY18-tau. For quantitating NeuN and PSD95 (Fig. 6), levels were first normalized to GAPDH and then normalized to WT-uninjected mice. At least 7 WT, 9 WT-AAV, 9 Fyn KO, and 9 Fyn KO-AAV mice were used.

Microglia or astrocytes were labeled with antibodies against Iba1(1:300 goat polyclonal, Abcam) or GFAP (1:400 mouse monoclonal, MilliporeSigma), respectively. The sections were also co-labeled with tau13 (1:5000 mouse monoclonal, gift from late Dr. Lester Binder) to show the expression of human tauP301L. For analyzing microglia, the entire hippocampus was imaged and the total number of Iba1 positive cells was manually counted. For analyzing astrocytes, the entire hippocampus was imaged and the GFAP positive area was thresholded, then converted to a percent positive area as described previously [74]. Three animals from each of the four groups were analyzed. To determine the number of neurons, sections were labeled with anti-NeuN (1:5000 mouse monoclonal, Millipore Sigma), and based on both NeuN positivity and morphology, neurons were counted from one 400X field in Ammon's Horn for each mouse. 3 WT, 3 WT-AAV, 3 Fyn KO, and 4 Fyn KO-AAV mice were examined.
Open field activity
The open field test was performed on 6 month old mice as described previously [15]. Briefly, mice were placed in a 40.6 × 40.6 × 36.8 cm open-field chamber (San Diego Instruments, San Diego, CA), 55 lx, for 20 min. Total activity was defined as total beam breaks throughout the entire box, and central activity was defined as beam breaks occurring in the center (15.2 × 15.2 cm). 8 WT, 21 WT-AAV, 10 Fyn KO, 8 Fyn KO-AAV (mod hydro) mice were used.

Elevated plus maze
Elevated plus maze was performed on 6 month old mice as described previously [87]. Briefly, a maze was constructed from stainless steel with a Plexiglas base (36 in. tall) and two pairs of arms (2 × 11 5/8 inches) intersecting at right angles. One pair of arms was closed and had six-inch walls on three sides. The two open arms lacked walls. A 2 × 2-in. intersection at the center of the maze connected the four arms. Naive mice were placed onto the center and allowed 5 min to roam freely. The time each animal spent in open arms was recorded. 15 WT, 18 WT-AAV, 10 Fyn KO, and 8 Fyn KO-AAV (mod hydro) mice were used.

Contextual fear conditioning
Contextual fear conditioning was performed on 6 month old mice as described previously [76], using a near-infrared video-equipped fear conditioning chamber (Med Associates, Inc., St. Albans, VT). On training day (day 1), acquisition of contextual fear conditioning was performed, where a mouse explored the chamber for 3 min and then received 5 shocks (1 s, 0.75 mA), administered 1 min apart through the grid flooring. Total training time was 8 min. On the testing day (day 2), context-evoked freezing was tested by returning the mouse to the conditioning chamber for 6 min without foot shocks. Freezing was defined as an absence of movement other than respiration and scored with VideoFreeze software (Med Associates, Inc.). 12 WT, 20 WT-AAV, 8 Fyn KO, and 9 Fyn KO-AAV (mod hydro) mice were used in Fig. 5. 8 Fyn KO (no hydro), 8 Fyn KO (mod hydro), 9 Fyn KO-AAV (mod hydro) and 6 Fyn KO-AAV (severe hydro) were used in SI Fig. 1B.

Statistical analysis
Statistical analysis was carried out with GraphPad Prism 7.0. Nonparametric t-test, unpaired parametric t-test, and two-way ANOVA with Tukey’s post hoc multiple comparisons were used to analyze data when appropriate. Mean ± standard error of the mean was used in all comparisons were used to analyze data when appropriate. Mean ± standard error of the mean was used in all comparisons were used to analyze data when appropriate. Mean ± standard error of the mean was used in all comparisons were used to analyze data when appropriate. Mean ± standard error of the mean was used in all comparisons were used to analyze data when appropriate. Mean ± standard error of the mean was used in all comparisons were used to analyze data when appropriate. Mean ± standard error of the mean was used in all comparisons were used to analyze data when appropriate. Mean ± standard error of the mean was used in all comparisons were used to analyze data when appropriate. Mean ± standard error of the mean was used in all comparisons were used to analyze data when appropriate. Mean ± standard error of the mean was used in all comparisons were used to analyze data when appropriate. Mean ± standard error of the mean was used in all comparisons were used to analyze data when appropriate.

Results

Injecting AAV- tauP301L at p0 caused widespread human tau expression
We used intracerebroventricular injection of AAV-tauP301L in P0 mouse pups to create a P301L tauopathy model [14]. As described previously [22], depleting Fyn can predispose mice to develop non-obstructive hydrocephalus. Thus all AAV injected Fyn KO mice were screened with MRI as described in Methods, classifying animals as normal, or with moderate or severe hydrocephalus (examples of MRI images of mice with different levels of hydrocephalus were shown in SI Fig. 1A). All AAV injected Fyn KO mice were found to have some degree of hydrocephalus; of the 22 injected Fyn KO mice, 9 had moderate hydrocephalus and 13 had severe hydrocephalus. In contrast, when 22 AAV injected WT mice were examined, none developed hydrocephalus, indicating that injection of AAV-tauP301L was not sufficient to induce hydrocephalus.

In order to control for the effects of hydrocephalus, Fyn KO-AAV mice with severe hydrocephalus, Fyn KO-AAV with moderate hydrocephalus, and uninjected Fyn KO mice, with moderate hydrocephalus or no hydrocephalus, were compared using behavioral tests. We found that Fyn KO mice with moderate hydrocephalus, either uninjected or injected with AAV, performed similarly to Fyn KO mice without hydrocephalus; only Fyn KO-AAV with severe hydrocephalus had abnormal behavior (SI Fig. 1B). We had also found that the Fyn KO-AAV with severe hydrocephalus had significantly higher levels of hyperphosphorylated tau than both WT-AAV and Fyn KO-AAV with moderate hydrocephalus (SI Fig. 2). Since our goal was to investigate the effects of Fyn KO, rather than the effects of hydrocephalus, Fyn KO-AAV mice with severe hydrocephalus were omitted from the study. Since Fyn KO-AAV with moderate hydrocephalus were similar in behavior to Fyn KO without hydrocephalus (SI Fig. 1B, C), such mice hereafter will simply be referred to as “Fyn KO-AAV”.

Injected mice were harvested at 6 months and the distribution of human tau expression was evaluated histologically. Using immunohistochemistry, human-specific tau13 antibody was used to label human tau (SI Fig. 3). High levels of human tau were detected in the hippocampal regions of both WT-AAV (SI Fig. 3A, D) and Fyn KO-AAV (SI Fig. 3B, E) mice. As expected, uninjected WT mouse brain showed no tau13 labeling (SI Fig. 3C, F). In the previous study using intracerebroventricular injection of AAV-tauP301L in P0 mouse pups, an AAV-GFP was injected as a control, showing that AAV injection alone was not sufficient to cause any of the tauP301L-induced effects [14].

Fyn depletion reduced the effects of tauP301L on NFT formation and abnormal tau hyperphosphorylation
At 6 months of age, WT-AAV mice displayed significant amounts of both Bielschowsky silver stained (Fig. 1a, c)
or Thioflavin S positive (Fig. 1f, h) tangles in the CA1–3 region of the hippocampus. In Fyn KO-AAV mice, a reduction in tangle pathology, relative to WT-AAV mice, was observed using Bielschowsky silver staining (Fig. 1b, d) or Thioflavin S (Fig. 1g, i). Upon quantitation of the Bielschowsky silver stain, we found that Fyn depletion resulted in a reduction of 79.6% in tangle pathology relative to WT-AAV (p = 0.0187). These results indicated that Fyn played an important role in NFT formation.

Given that NFT contain tau species that are abnormally phosphorylated, we examined the effect of Fyn depletion on tau hyperphosphorylation since Fyn is able to both directly and indirectly affect tau phosphorylation. WT-AAV mice displayed strong immunoreactivity to antibodies targeting pS199/pS202 (Fig. 2a), pY18 (Fig. 2d), and pT231 (Fig. 2g) in the hippocampus. In contrast, Fyn KO-AAV mice had a 61.4% reduction of pS199/pS202 (Fig. 2b, c, p = 0.0035), 69.5% reduction of pY18 (Fig. 2e, f, p < 0.0001), and 66.1% reduction of pT231 (Fig. 2h, i, p = 0.0037). Since pY18-tau persisted in Fyn KO-AAV (Fig. 2e), another tyrosine kinase was still acting on tau in the absence of Fyn.

To assess the total level of phosphorylated tau species, soluble lysates from AAV injected WT and Fyn KO brains were subjected to western blot analysis using AT8 (pS199/S202) and pY18 antibodies. Since we had injected AAV-tauP301L by hand, variability in tau expression might arise. To account for this possibility, we also probed the lysates with tau5, an antibody that detected both mouse and human tau, independent of phosphorylation. This allowed us to measure total tau levels for each injected mouse and to normalize pS199/S202 or pY18 levels to total tau levels; a scatter plot was used to display the normalized values. This analysis revealed that Fyn KO-AAV mice had a 72.4% decrease in pS199/pS202 (p = 0.0106) and a 44.0% decrease in pY18 levels (p = 0.0168) relative to WT-AAV (Fig. 3b, c). Uninjected mice were also examined, but pS199/pS202, pY18, and human tau were not detected (Fig. 3a). The total tau levels between Fyn KO-AAV and WT-AAV were not significantly different (p = 0.0532) (Fig. 3b, c).
Fyn depletion attenuated AAV-tauP301L induced microgliosis

Several lines of evidence indicate that tau pathology is associated with inflammation in both human tissues [19, 20, 30] and animal models [3, 45, 88] and that increasing inflammation also worsens tau pathology [34, 38, 51]. Similar to results from Cook et al. [14], we also observed that AAV-tauP301L expression in WT mice caused a significant increase in the number of Iba1 positive microglia in the hippocampus (p = 0.0002, Fig. 4a, c). AAV-tauP301L expression also caused an elevated percent area of GFAP positive astrocytes in the same brain regions (p = 0.0087, Fig. 4d) compared to WT and Fyn KO mice.

Interestingly, Fyn has also been shown to play a role in oligodendrocyte differentiation [77], astrocyte migration [18], and in the production of inflammatory cytokines in natural killer cells [61]. In models of Alzheimer’s disease, Parkinson’s disease, and epilepsy, Fyn has also been implicated in modulating the neuroinflammatory response [55, 57, 70, 80]. We found that while tauP301L increased microgliosis in WT mice, AAV injected Fyn KO mice did not experience tauP301L-induced microgliosis when compared to WT mice (p = 0.9027; Fig. 4a, c). For astrocytosis, a similar result was obtained, where the Fyn KO and Fyn KO-AAV had a similar level of percent GFAP positive area (p=0.9473; Fig. 4d).

Both Fyn depletion and AAV-tauP301L caused behavioral abnormalities

To determine how Fyn depletion impacted tauP301L-induced behavioral abnormalities, we evaluated performance on tasks designed to assess learning and memory as...
well as anxiety, which were all clinical manifestations of FTDP-17. In the open field assay, although none of the mice experienced significant differences in total movement (Fig. 5a), uninjected Fyn KO mice spent less time in the center of the apparatus compared to uninjected WT mice ($p = 0.0002$; Fig. 5b), indicating an anxiety phenotype. In the elevated plus maze, none of the mice experienced significant differences in time spent in the open arms (Fig. 5c). However, we did note that if the comparison was restricted to just the two groups, using parametric t test (SI Table 1), WT-AAV injected mice behaved significantly differently, relative to WT mice, in both the open field assay ($p = 0.0333$, Fig. 5b) and the elevated plus maze ($p = 0.0342$, Fig. 5c). Such a result agreed with data obtained by Cook and colleagues who used both the p0 AAV-tau$^{P301L}$ approach [14], and the rTg4510 tauopathy mouse model [13]. In addition, we also noted that relative to uninjected WT mice, uninjected Fyn KO mice also behaved differently in elevated plus maze ($p = 0.0022$, SI Table 1) if the comparison was restricted to just the two groups, using parametric t test.

In contextual fear conditioning, WT-AAV injected mice, relative to WT uninjected mice showed significant learning deficits during acquisition of shock on training day (day 1) (Fig. 5d) and significant memory deficit during the recall of shock in context on testing day (day 2) (Fig. 5e), as analyzed with two-way ANOVA. Interestingly, besides having a role in mediating anxiety behaviors (Fig. 5b), Fyn is also known to play a role in LTP and memory formation, which is consistent with our finding that uninjected Fyn KO mice displayed significant learning and memory deficits in contextual fear conditioning relative to WT uninjected mice (Fig. 5d, e). However, unlike WT-AAV, Fyn KO-AAV mice did not exhibit any learning (Fig. 5d) or memory deficits (Fig. 5e) relative to its uninjected mice. This agreed with our finding that Fyn KO-AAV mice did not experience any abnormalities in anxiety behaviors relative to Fyn KO uninjected mice (Fig. 5b, c). Lastly, we noted that the
deficits exhibited by the uninjected Fyn KO mice were either similar to (Fig. 5c, d) or larger (Fig. 5b, e) than those exhibited by WT-AAV. Fyn depletion prevented tauP301L-induced synaptic protein degradation while no neuronal cell loss was detected in AAV injected mice.

To determine whether the behavioral deficits experienced by the WT-AAV mice were due to overt neuronal loss or more subtle synaptic abnormalities, we first probed whole brain crude lysates for NeuN, as a marker for neurons, and for PSD95, as a synaptic marker, in WT, WT-AAV, Fyn KO, and Fyn KO-AAV mice. In the crude brain lysates, there was no statistical difference in NeuN for all four groups of mice (Fig. 6A, B left, SI Table 1). However, we found that in PSD95, WT-AAV had a 39.1% reduction relative to WT uninjected mice ($p = 0.0049$), a 39.6% reduction relative to Fyn KO uninjected and Fyn KO-AAV mice, as shown in Fig. 4.
uninjected ($p = 0.0021$), and a 43.3% reduction relative to Fyn KO-AAV ($p = 0.00005$; Fig. 6a, b right). There was no difference between WT uninjected and Fyn KO uninjected mice ($p = 0.9999$), between WT uninjected and Fyn KO-AAV ($p = 0.9073$), or between Fyn KO and Fyn KO-AAV ($p = 0.9162$; Fig. 6a, b right). We also examined brain slices stained with anti-NeuN and found no differences between the different groups in the total number of neurons in the Ammon’s horn of the hippocampus (Fig. 6c, SI Table 1).

To further characterize the synaptic integrity of the mice, we obtained crude synaptosome preparations from

![Graphs](image-url)
WT, WT-AAV, Fyn KO, and Fyn KO-AAV brains and probed for postsynaptic markers such as PSD 95 and NR2B. Again, we found that relative to WT uninjected mice, WT-AAV mice had a 70.3% decrease in PSD95 ($p = 0.027$) (Fig. 7a, b). The 34.3% decrease in NR2B levels was not significant by two-way ANOVA ($p = 0.3607$) but was significant if only WT and WT-AAV were compared using the unpaired t-test ($p = 0.0304$, SI Table 1). Similar to our previous findings [46], Fyn KO uninjected animals had no changes in PSD95 ($p = 0.4378$) or NR2B ($p = 0.9986$) when compared to WT uninjected animals (Fig. 7a,b; SI Table 1), indicating that Fyn depletion itself did not cause alterations in synaptic integrity at 6 months of age. When examining the Fyn KO-AAV mice, we found that the levels of PSD95 and NR2B in Fyn KO-AAV mice were comparable to their levels in either WT uninjected mice or Fyn KO uninjected mice (Fig. 7b, 5B; SI Table 1). Therefore, our data showed that Fyn depletion was able to reverse tau$_{P301L}$ induced synaptic loss. Interestingly, the WT-AAV synaptosome preps also had a 62.5% decrease in Fyn when compared to uninjected WT mice (Fig. 7a, b) ($p = 0.0024$), an effect that may be due to the overall loss of PSD protein. Our data supports findings by other investigators where mice expressing tau$_{P301L}$ at 6 months of age displayed synaptic loss without overt neuronal loss [14, 16, 64, 69].

Discussion
In this study, we reproduced the P301L tauopathy mouse model using injection of AAV-tau$_{P301L}$ into P0 WT mouse brain, as previously described [14], then used
the same strategy to investigate the role of Fyn by injecting Fyn KO P0 brains. In the WT mice, we reproduced the results of Cook et al., where widespread expression of human tau was reported, together with tau hyperphosphorylation, neurofibrillary tangles, inflammation, behavioral abnormalities, and loss of postsynaptic markers [14]. In working with homozygous Fyn KO mice, one caveat was their tendency to develop non-obstructive hydrocephalus [22]. In our study, given that WT-AAV injected mice did not develop hydrocephalus, AAV-tauP301L injection did not correlate with the occurrence of hydrocephalus. However, the combination of the P0 brain injection and the homozygous Fyn KO trait resulted in a higher incidence of hydrocephalus. Nevertheless, by eliminating mice with severe hydrocephalus, we were able to show that depleting Fyn (1) reduced tauP301L-induced abnormal tau hyperphosphorylation and NFT formation and (2) prevented tauP301L-induced microgliosis and synaptic loss. These data provide evidence for Fyn as an essential protein involved in the disease pathogenesis of tauopathies.

In terms of regulating tau phosphorylation at Y18, Fyn depletion reduced but did not eliminate pY18. Since our lab has found that both Fyn and Src can phosphorylate this residue [42], Src may phosphorylate Y18 in a Fyn KO. Moreover, other tyrosine kinases such as Syk [40] and Lck [68] have also been reported to phosphorylate Y18. This suggests that the phosphorylation of Y18 is sufficiently important such that in spite of the absence of Fyn, the residue is phosphorylated. The importance of pY18-tau for glutamate-induced calcium influx and excitotoxicity in neurons has been shown [54]. As for ser/thr

![Image of Western blots showing the effect of Fyn depletion on synaptic protein degradation.](image-url)
phosphorylation, we found that depleting Fyn caused a significant reduction in phosphorylation of tau at a Cdk5 site (S199/S202) and a GSK3β site (T231), suggesting that depletion of Fyn may have resulted in the reduction of Cdk5 and GSK3β activities. In the Fyn KO, the reduction in tau hyperphosphorylation correlated with a reduction in Bielschowsky silver stained and thioflavin S positive NFT. While our findings did not rule out effects caused by potential strain differences, our data suggested that Fyn is critical for NFT formation.

In our somatic transgenic model, we were also able to replicate the neuroinflammatory changes, such as the prominent microgliosis and astrogliosis associated with tauP301L expression [14, 28, 45, 51]. Our data showed that Fyn depletion was able to eliminate the effects of AAV-tauP301L injection on microgliosis and astrogliosis, providing evidence that Fyn plays an important role in the microglial inflammatory response in tauopathies.

Lastly, the impact of Fyn depletion on tauP301L-induced behavioral deficits was investigated. Our WT-AAV injected mice developed aberrant exploratory behavior and cognitive deficits that were also found in other transgenic FTDP-17 tauopathy mouse models [62]. At 6 months of age, these deficits have been attributed to tauP301L-induced changes in dendritic spine architecture, synaptic dysfunction and loss, and abnormalities in electrophysiology, all preceding NFT deposition and neuronal loss in the rTg4510 transgenic FTDP tauopathy mouse model [14, 16, 64]. Our findings are consistent, as our data also showed losses in postsynaptic proteins without neuronal cell loss in WT-AAV.

In analyzing the behavioral deficits of Fyn KO-AAV, we found that the introduction of tauP301L was not able to induce further deficits in the behaviors of Fyn KO mice (Fig. 5). However, Fyn KO mice were already known to have abnormal exploratory behavior and cognitive deficits relative to WT mice [31, 46, 53], stemming from Fyn’s role in mediating LTP and memory formation through the phosphorylation of NMDARs [23, 35, 56, 83]. Therefore, the Fyn KO mice may already be performing at such a low level that further decreases might not be possible no matter the insult, such as tauP301L (also known as the “floor effect”). Moreover, it was difficult to determine whether tauP301L required Fyn to induce behavior abnormalities or that the deficits caused by Fyn depletion alone superseded those induced by tauP301L. The latter possibility (the “floor effect”) was supported by our finding that in two tests, the Fyn KO mice had significantly more deficits than the WT-AAV (Fig. 5b, e, SI Table 1). The fact that Fyn KO and Fyn KO-AAV both had normal levels of PSD95 and NR2B (Figs. 6 and 7) suggested that Fyn KO had no synapse loss and that tauP301L could not induce synapse loss in the absence of Fyn. These findings suggest that synapse loss cannot be used to explain the behavioral deficits of the Fyn KO and Fyn KO-AAV mice.

In summary, using AAV to create a P301L tauopathy mouse model on a Fyn KO background, we have found that Fyn was critical for neurofibrillary tangle formation and tau hyperphosphorylation. Our data suggests that reducing Fyn activity might be an effective therapy for tauopathies. However, given the importance of Fyn in normal physiological processes, such therapy would be difficult, especially since dementia patients usually have reduced cognitive reserves. Thus, more specific therapies aimed at targeting either disease related processes involving Fyn or Fyn interaction partners may yield a more desirable therapeutic result; the recent report of a peptide inhibitor of the tau-Fyn interaction [65] is a first step in this direction. In closing, as Aβ oligomers had no role in these findings, Fyn alone has an important role in tauopathy.

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s40478-020-00979-6.

Additional file 1. Supplementary Information

Acknowledgements
We thank Dr. Peter Davies (Feinstein Institute for Medical Research, NY) for generously providing the CP17 antibody. We also thank Drs. Dan Thedens (University of Iowa, IA) for help with MRI, John Wemmie (University of Iowa, IA) for the use of facilities to investigate mouse behavior, and John Crary (Mount Sinai School of Medicine, NY) for technical assistance with staining.

Authors’ contributions
G. Liu and G. Lee made substantial contributions to the conception and design of the work and to the acquisition, analysis, and interpretation of the data. G. Liu and G. Lee also drafted the work or substantially revised it. KF, YL and TEG made substantial contributions to the acquisition of data. M. Hefti and YL read and approved the final manuscript.

Funding
G Loss received support from NIH/NIA R01 AG017753 and Alzheimer’s Association IIRG-12-241042. G Liu was supported by NIH/NIA F30 AG054134 and by Iowa Neuroscience Institute Kwak-Fergusson Fellowship. M. Hefti receives support from NIH/NINDS K23 NS109284.

Availability of data and materials
All data used/analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval
Animal care complied with National Institutes of Health guidelines for the care and use of laboratory animals and all animal procedures were approved by the University of Iowa Institutional Animal Care and Use Committee.

Consent for publication
Not applicable.

Competing interests
TE Golde is a cofounder of Lacerta Therapeutics Inc. and a member of their Scientific Advisory Board. The other authors declare no competing financial interests.
Author details
1Interdisciplinary Program in Neuroscience, University of Iowa Carver College of Medicine, Iowa City, IA, USA. 2Department of Pathology, University of Iowa Carver College of Medicine, Iowa City, IA, USA. 3Department of Neuroscience, University of Iowa Carver College of Medicine, Iowa City, IA, USA. 4Department of Internal Medicine, University of Florida, Gainesville, FL, USA. 5Department of Neuroscience, University of Iowa Carver College of Medicine, 500 Newton Road, ML B191, Iowa City, IA 52242, USA.

Received: 29 April 2020 Accepted: 24 June 2020
Published online: 14 July 2020

References
1. Ballatore C, Lee VM, Trojanowski JQ (2007) Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci 8:663–672
2. Bhaskar K, Hobbs GA, Yen SH, Lee G (2005) Disease-related modifications in tau affect the interaction between Fyn and tau. J Biol Chem 280:35139–35125
3. Bhaskar K, Yen SH, Lee G (2005) Disease-related modifications in tau affect the interaction between Fyn and tau. J Biol Chem 280:35139–35125
4. Bhaskar K, Hobbs GA, Yen SH, Lee G (2005) Disease-related modifications in tau affect the interaction between Fyn and tau. J Biol Chem 280:35139–35125
5. Boehm J (2013) A ‘danse macabre’: tau and Fyn in STEP with amyloid beta precipitates and with defects in oligodendrocyte development. Mol Cell Neurosci 58:452–465
6. Braithwaite SP, Adkisson M, Leung J, Nava A, Masterson B, Urfer R, Starzyk JA, Oksenberg D, Nikolich K (2006) Regulation of NMDA receptor trafficking and function by striatal-enriched tyrosine phosphatase (STEP). J Neurosci 26:8247–8256
7. Brandt R, Leger J, Lee G (1995) Interaction of tau with the neural plasma membrane mediated by tau's amino-terminal projection domain. J Cell Biol 129:1327–1340
8. Carter GS, Vogel TW, Zhang Q, Seo S, Swiderski RE, Moninger TO, Cassell MJ, Borchelt DR, Kim JY, Jankowsky JL et al (2013) Capsid serotype Φ29 enhances serotype-specific transduction of neural stem cells in vivo and recapitulates multiple aspects of HIV-1 transduction. J Virol 87:11906–11918
9. Chakrabarty P, Rosario A, Cruz P, Siemienski Z, Ceballos-Diaz C, Crosby K, Masliah E, Mucke L (2005) Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer's disease. J Neurosci 25:9694–9702
10. Chin J, Palsop JJ, Purolivak J, Massaro C, Biely N, Gerstein H, Scearce-Levie K, Masliah E, Mucke L (2005) Fyn kinase coordinates synaptic activity and timing of injection determines AAV transduction in the neonatal mouse brain. PLoS One 8:e67660
11. Chin J, Palsop JJ, Yu GQ, Kojima N, Masliah E, Mucke L (2004) Fyn kinase modulates synaptotyphy, but is not aberrant sprouting, in human amyloid precursor protein transgenic mice. J Neuroscience 24:4692–4697
12. Clark LN, Poorkaj P, Wszolek Z, Geschwind DH, Nasreddine ZS, Miller B, Li D, Payami H, Aweret F, Markopulu K et al (1998) Pathogenic implications of mutations in the tau gene in pallido-ponto-nigral degeneration and related neurodegenerative disorders linked to chromosome 17. Proc Natl Acad Sci USA 95:13103–13107
13. Cook C, Dunmore JH, Murray ME, Scheffel K, Shukoor N, Tong J, Castanedes-Casey M, Phillips V, Rousseau L, Pulenier M et al (2014) Severe amygdala dysfunction in a MAPT transgenic mouse model of frontotemporal dementia. Neurobiol Aging 35:1769–1777
14. Cook C, Kang SS, Cafarmano Y, Lin WL, Yue M, Kurti A, Shinohara M, Jansen-West K, Perksen E, Castanede-Casey M et al (2015) Tau deposition drives neuropathological, inflammatory and behavioral abnormalities independently of neuronal loss in a novel mouse model. Hum Mol Genet 24:6198–6212
15. Corryell MW, Ziemann AE, Westmoreland PJ, Haenfler JM, Kurjakovic Z, Zha XM, Price M, Schnizler MK, Wemmie JA (2007) Targeting pharmacologically active amyloid-beta peptides reduces innate fear and alters neuronal activity in the fear circuit. Biol Psychiatry 62:1104–1110
16. Crimins JL, Rocher AB, Luebke JL (2012) Electrophysiological changes precede morphological changes to frontal cortical pyramidal neurons in the rtg4510 mouse model of progressive tauopathy. Acta Neuropathol 124:777–795
17. Dehmelt L, Halpain S (2005) The MAP 2/tau family of microtubule-associated proteins. Genome Biol 6:204
18. Dey N, Crosswell HE, De P, Parsons R, Peng Q, Su JD, Dirden DL (2008) The protein phosphatase activity of Pten regulates SRF family kinases and controls glioma migration. Cancer Res 68:1862–1871
19. Gebicke-Haerter PJ (2001) Microglia in neurodegeneration: molecular aspects. Microsc Res Tech 54:47–58
20. Gerhard A, Pavese N, Hotton G, Turkheimer F, Es M, Hammers A, Eggert K, Oertel W, Banati RB, Brooks DJ (2006) In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol Dis 21:404–412
21. Goedert M, Eisenberg DS, Crowther RA (2017) Propagation of tau aggregates and neurodegeneration. Annu Rev Neurosci 40:189–210
22. Goto T, Tezuka T, Nakazawa T, Sagara H, Yamamoto T (2008) Loss of Fyn tyrosine kinase on the C57BL/6 genetic background causes hydrocephalus with defects in oligodendrocyte development. Mol Cell Neurosci 38:203–212
23. Grant SG, O'Dell TJ, Karl KA, Stein PL, Soriano P, Kandel ER (1992) Impaired long-term potentiation, spatial learning, and hippocampal development in fyn mutant mice. Science 258:1903–1910
24. Hanger DP, Hughes K, Woodgett JR, Brion JP, Anderton BH (1992) Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: generation of paired helical filament epitopes and neuronal localisation of the kinase. Neurosci Lett 147:58–62
25. Hashiguchi M, Saito T, Hisanaga S, Hashiguchi T (2002) Truncation of CDK5 activator p35 induces intensive phosphorylation of Ser202/Thr205 of human tau. J Biol Chem 277:44525–44530
26. Ho GJ, Hashimoto M, Adame A, Izu M, Aflord MF, Thai LL, Hansen LA, Masliah E (2005) Altered p56fyn kinase expression accompanies disease progression in Alzheimer's disease: implications for its functional role. Neurobiol Aging 26:625–635
27. Hoover BR, Reed MN, Su J, Penrod RD, Kistilin LA, Grant MK, Pistorik R, Gefson GA, Lanier YM, Yuan LL et al (2010) Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neurology 68:1067–1081
28. Hunsberger HC, Rudy CC, Weitzen DS, Zhang C, Tosto DE, Knowlani K, Xu Y, Reed MN (2014) Effect size of memory deficits in mice with adult-onset P301L tau expression. Behav Brain Res 272:181–195
29. Hutton M, Lendon CL, Rizzu P, Baker M, Froelich A, O'Neill DM, Thedens DR, Keppler-Noreuil KM, Nopoulos P et al (2012) Association of missense and S5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393:702–705
30. Isihazka K, Dickson DW (2001) Microglial activation parallells system degeneration in progressive supranuclear palsy and corticobasal degeneration. J Neuropathol Exp Neurol 60:647–657
31. Itooka T, Hattori K, Kida S, Kolino T, Nakazawa T, Yamamoto T, Yagi T, Yusa S (2008) Activation of Fyn tyrosine kinase in the mouse dorsal hippocampus is essential for contextual fear conditioning. J Neurosci 28:973–981
32. Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, Wölfing H, Chiang BC, Christie MJ, Napier IA et al (2010) Dendritic function of tau mediates amyloid-β toxicity in Alzheimer's disease mouse models. Cell 142:387–397
33. Kaufman AC, Salazar SV, Haas LT, Yang J, Kostylev MA, Jeng AT, Robinson SA, Gunther EC, van Dyck CH, Nyaagda HB et al (2015) Fyn inhibition rescues established memory and synapse loss in Alzheimer mice. Ann Neurol 77:953–971
34. Kitazawa M, Oddo S, Yamasaki TR, Green KN, LaFerla FM (2005) Lippopolysaccharide-induced inflammation exacerbates tau pathology by a cycin-dependent kinase S-mediated pathway in a transgenic model of Alzheimer's disease. J Neurosci 25:8893–8893
35. Kojima N, Wang J, Mansuy IM, Grant SG, Mayford M, Kandel ER (1997) Reversing impairment of long-term potentiation in Fyn-deficient mice by introducing Fyn transgene. Proc Natl Acad Sci U S A 95:13103–13107
36. Krstic D, Madhusudan A, Doehner J, Vogel P, Notter T, Imhof C, Manalastas A, Hilfiker M, Pfister S, Schwerdel C et al (2012) Systemic immune challenges
trigger and drive Alzheimer-like neuropathology in mice. J Neuroinflammation 9:151

39. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Locsatos M, Morgan TE, Rozovskiy I, Trommer B, Viola N et al. (1998) Diffusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A 95:6448–6453

40. Lebouvier T, Scales TM, Williamson R, Noble W, Dyckdaets C, Hanger DP, Reynolds CH, Anderton BH, Derkinderen P (2009) The microtubule-associated protein tau is also phosphorylated on tyrosine. J Alzheimer’s Dis 18:1–9

41. Lee G, Newman ST, Gard DL, Band H, Panchamoorthy G (1998) Tau interacts with src-family non-receptor tyrosine kinases. J Cell Sci 111(Pt 21):3167–3177

42. Lee G, Thangavel R, Sharma VM, Litterer JY, Bhaskar K, Fang SM, Do LH, Andreatis A, Van Hoesen G, Kiseiz-Arden H (2004) Phosphorylation of tau by fyn: implications for Alzheimer’s disease. J Neurosci 24:2304–2312

43. Lesort M, Jope RS, Johnson GV (1999) Insulin transiently increases tau phosphorylation: involvement of glycogen synthase kinase-3B and Fyn tyrosine kinase. J Neurochem 72:576–584

44. Leugers CJ, Lee G (2010) Tau potentiates nerve growth factor-induced mitogen-activated protein kinase signaling and neurite initiation without a requirement for microtubule binding. J Biol Chem 285:19125–19134

45. Lewis J, McGowan E, Rockwood J, Melrose H, Nacharaju P, Van Slentenhorst M, Gwinn-Hardy K, Paul Murphy M, Baker M, Yu X et al. (2000) Neurofibrillary tangles, amyotrophy and progressive motor degeneration in mice expressing mutant (P301L) tau protein. Nat Genet 25:402–405

46. Liu G, Thangavel R, Rusted L, Kim Y, Francis MB, Adams E, Lin Z, Taugh RJ, Wemmje JA, Usachey YM et al. (2019) Loss of tau and Fyn reduces compensatory effects of MAP 2 for tau and reveals a Fyn-independent effect of tau on cognition. J Neurosci Res 97:1393–1413

47. Lund ET, McKenna R, Evans DB, Sharma SK, Mathews WR (2001) Characterization of the in vitro phosphorylation of human tau by tau protein kinase II (cdk5/p25) using mass spectrometry. J Neurochem 76:1221–1232

48. Luo YQ, Hiroshima N, Li YH, Alkon DL, Sunderland T, Etcheberrigaray R, Wemmje JA, Usachey YM et al. (2019) Loss of tau and Fyn reduces compensatory effects of MAP 2 for tau and reveals a Fyn-independent effect of tau on cognition. J Neurosci Res 97:1393–1413

49. Mandelkow EM, Drewes G, Biernat J, Gustke N, Van Lint J, Vandenheede JR, Mandelkow E (1992) Glycogen synthase kinase-3 and the Alzheimer-like state of microtubule-associated protein tau. FEBS Lett 314:315–321

50. Mandelkow EM, Mandelkow E (2012) Biochemistry and cell biology of tau protein in neurofibrillary degeneration. Cold Spring Harb Perspect Med 2:a006247

51. Maphis N, Xu G, Kokiko-Cochran ON, Jiang S, Cardona A, Ransohoff RM, Mandelkow EM, Gwinn-Hardy K, Paul Murphy M, Baker M, Yu X et al. (2000) Neurofibrillary tangles, amyotrophy and progressive motor degeneration in mice expressing mutant (P301L) tau protein. Nat Genet 25:402–405

52. Rush T, Roth JR, Thompson SJ, Aldaher AR, Cochran JN, Roberson ED (2020) A peptide inhibitor of tau-Sh3 interactions ameliorates amyloid-beta toxicity. Neurobiol Dis 134:104668

53. Schindowsk K, Bretteville A, Leroy K, Begard S, Brion JP, Hamdane M, Buee L (2006) Alzheimer’s disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutant tau transgenic mouse without any motor deficits. Am J Pathol 169:599–616

54. Sharma S, Carlson S, Puttachary S, Sarkar S, Showman L, Putta M, Kanthasamy AG, Thippeswarw T (2018) The Role of Fyn-PRICKLE signaling in SE-induced neuroinflammation and epileptogenesis in experimental models of temporal lobe epilepsy. Neurobiol Dis 110:102–121

55. Sharma VM, Litzers JM, Bhaskar K, Lee G (2007) Tau impacts on growth-factor-stimulated actin remodeling. J Cell Sci 120:748–757

56. Shirazi SK, Wood JS (1993) The protein tyrosine kinase, fyn, in Alzheimer’s disease pathology. Neuroreport 4:435–437

57. Sims, H, Babic Leko M, Wu, S, Harring F, C, Delalle, J, Jovanov-Milosevic N, Izadodona D, Buee L, de Silva R, D, Giovanni G et al. (2016) Tau protein hyperphosphorylation and aggregation in Alzheimer’s disease and other tauopathies, and possible neuroprotective strategies. Biomolecules 6:66

58. Singh-Bains MK, Linke V, Austria MDR, Tan AYS, Scatter EL, Mehrabi NF, Faull RLM, Dragunow M (2019) Altered microglia and neurovasculature in the Alzheimer’s disease cerebellum. Neurobiol Dis 132:104589

59. Snyder EM, Nong Y, Almeda CG, Paul S, Moran T, Choi, EY, Nairn AC, Saltar MW, Lombrosio PJ, Gousas HK et al. (2005) Regulation of NMDA receptor trafficking by amyloid-β. Nat Neurosci 8:1051–1058

60. Sowers LP, Loo L, Wu Y, Campbell E, Ulrich JD, Wu S, Paemka L, Wassink T, Meyer B, Cing X et al. (2013) Disruption of the non-canonical Wnt gene PRCKCε leads to autism-like behaviors with evidence for hippocampal synaptic dysfunction. Mol Psychiatry 18:1077–1089

61. Spalter BR, Boyle-Walsh EA, Engleka MJ, Gadue P, Schellenberg GD (1998) Tau is a presenile dementia. Proc Natl Acad Sci U S A 95:7737–7741

62. Stuart LM, Bell SA, Stewart CR, Silver JM, Richard J, Goss JL, Tseng AA, Zhang A, E, Hoy Whu, JB, Moore KJ (2007) CD36 signals to the actin cytoskeleton and regulates microglial migration via a p130Cas complex. J Biol Chem 282:27392–27401
81. Tapia-Rojas C, Cabezas-Opazo F, Deaton CA, Vergara EH, Johnson GVW, Quintanilla RA (2019) It’s all about tau. Prog Neurobiol 175:54–76
82. Teravskis PJ, Oxnard BR, Miller EC, Kemper L, Ashe KH, Liao D (2019) Phosphorylation in two discrete tau domains regulates a stepwise process leading to postsynaptic dysfunction. J Physiol https://doi.org/10.1113/JP277459
83. Tezuka T, Urmenoti H, Akiyama T, Nakanishi S, Yamamoto T (1999) PSD-95 promotes Fyn-mediated tyrosine phosphorylation of the N-methyl-D-aspartate receptor subunit NR2A. Proc Natl Acad Sci U S A 96:435–440
84. Um JW, Kaufman AC, Kostylev M, Heiss JK, Stagi M, Takahashi H, Kerrisk ME, Vortmeyer A, Wisniewski T, Koleske AJ et al (2013) Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer Aβ oligomer bound to cellular prion protein. Neuron 79:887–902
85. Um JW, Nygaard HB, Heiss JK, Kostylev MA, Stagi M, Vortmeyer A, Wisniewski T, Gunther EC, Strittmatter SM (2012) Alzheimer amyloid-β oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. Nat Neurosci 15:1227–1235
86. Um JW, Strittmatter SM (2013) Amyloid-β induced signaling by cellular prion protein and Fyn kinase in Alzheimer disease. Prion 7:37–41
87. Wemmie JA, Askwith CC, Lamani E, Cassell MD, Freeman JH Jr, Welsh MU (2003) Acid-sensing ion channel 1 is localized in brain regions with high synaptic density and contributes to fear conditioning. J Neurosci 23:496–502
88. Wes PD, Easton A, Corradi J, Barten DM, Devidze N, DeCarr LB, Truong A, He A, Barreto L, Polkon C et al (2014) Tau overexpression impacts a neuroinflammation gene expression network perturbed in Alzheimer’s disease. PLoS One 9e106050
89. Williamson R, Scales T, Clark BR, Gibb G, Reynolds CH, Kellie S, Bird IN, Varndell IM, Sheppard PW, Everall I et al (2002) Rapid tyrosine phosphorylation of neuronal proteins including tau and focal adhesion kinase in response to amyloid-β peptide exposure: involvement of Src family protein kinases. J Neurosci 22:10–20
90. Wood JG, Zinsmeister P (1991) Tyrosine phosphorylation systems in Alzheimer’s disease pathology. Neurosci Lett 121:12–16

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.